Serum hepcidin may be an early predictive biomarker for ruling out contrast-induced acute kidney injury (CI-AKI) after percutaneous coronary interventions (PCI), according to investigators.
They report in Advances in Medical Sciences that monitoring serum hepcidin levels following PCI may allow for early patient risk stratification.
Jolanta Malyszkoa, of the Medical University of Bialystok, Bialystok, Poland, and colleagues studied 89 patients undergoing elective PCI due to stable angina (II/III CCS class). They excluded patients with preexisting chronic kidney disease (CKD). Of these, 8% experienced CI-AKI.
The study demonstrated a significant rise in serum hepcidin as early as 4 and 8 hours after PCI compared with baseline values. Serum neutrophil gelatinase-associated lipocalin (NGAL) increased after 2, 4, and 8 hours. Urinary NGAL increased after 4, 8, and 24 hours. Urinary hepcidin, however, fell significantly 8 and 24 hours after PCI. Serum cystatin C increased significantly 8 hours after PCI, peaking 24 hours after the procedure, and then decreasing after 48 hours.
Urine hepcidin levels were significantly lower 8 and 24 hours after PCI in patients with CI-AKI, but serum and urine NGAL were significantly higher in these patients.
“Our findings suggest that serum hepcidin might be an early predictive biomarker of ruling out CI-AKI after PCI,” the authors concluded. These data need to be validated in large cohorts with various stages of CKD, they noted.
Malyszko J, Bachorzewska-Gajewskac H, Malyszko JS, et al. Hepcidin – Potential biomarker of contrast-induced acute kidney injury in patients undergoing percutaneous coronary interventions. Adv Med Sci. 2019;64:211-215.